Chief Executive Officer
Group General Counsel
Chief Operating Officer
Chief Commercial Officer & General Manager West World
Chief Financial Officer
Chief Human Resources Officer
General Manager China / Asia-Pacific
Chief Innovation & Development Officer
General Manager India
Key facts of SGD Pharma
Turnover: 347.5 M€
(2020 Sales Forecast)
Global production capacity:
+ 2 Billion vials per year
1 sorting facility
1 decoration warehouse
Geographical areas: worldwide scope
90 agents & distributors
10 sales offices
Products’ categories & market applications:
- Parenteral: molded injectable vials, tubular injectable vials, infusion bottles, ampoules
- Oral: syrup bottles, tablet bottles, aerosol bottles, single dose bottles, droppers, bottles for antibiotics with filling mark
- Baby bottles
- Nasal bottles
- Diagnostic bottles
- Special needs: New designs & Innovation, plastic coating & printing, internal siliconization, ready-to-use, complete packs
Vials are carefully designed and manufactured with the highest integrity, ideally suited to a diverse range of application needs.
32% of women in top
2135 perm contracts
944 temporary contracts
369 person recruited in 2020
PAI Partners (PAI), a leading European private equity firm, becomes SGD Pharma new shareholder.
Introduction of Type I molded glass enhanced offer: three distinct solutions - AXess, AXecure and AXpert - to help customers make an optimized choice, well-matched for specific requirements.
Ambitious capacity extension plan of Vemula plant (tubular) to reach a tubular production capacity of 1 billion pieces by 2024.
SGD Pharma starts a major Sucy-en-Brie plant development project, investing over 31M€ to rebuild one of the furnaces and modernize the site.
Introduction of Ensiemo, the new complete child-resistant packaging solution for CBD oils. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed its first complete packaging solution & services, Ensiemo: a wide range of dropper bottles and dropper, in clear or amber glass.
As part of its continuous improvement program, SGD Pharma optimized in 2020 the clear Type I glass composition of its best-in-class manufacturing plant at Saint-Quentin-Lamotte. This implementation provides a more robust process to improve the stability of the glass quality, improves the chemical resistance to reduce interaction with sensitive drug formulation and answers to stricter regulatory requirements.
Introduction of Sterinity. The Sterinity platform in partnership with Stevanato Group – a recognized RTU platform for injectable vials by the pharmaceutical industry - offers high quality pre-sterilized Type I molded glass to speed up aseptic filling processes and reduces time-to-market for high value parenteral drugs.
India plant's new Unit V is fully operational and 100% dedicated to our tubular product range.
Launch of Clareo. This new innovative range of vials offers a combination of homogeneous wall thickness and superior cosmetic quality, which is unique for the molded glass Type II market. Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability are the main characteristics of Clareo.
SGD Pharma unveils its new identity. The new mission, vision and guiding principles support an ambitious growth strategy and a long-term vision for SGD Pharma.
JIC (China Jianyin Investment Ltd) becomes SGD Group new shareholder.
The new plant at Saint-Quentin-Lamotte produces its first glass vial on September 11th. December 21st marks the end of the pharmaceutical glass production at Mers-les-Bains after 57 years dedicated to this activity.
New manufacturing factory in Picardie at Saint-Quentin-Lamotte. SGD launched the newest, most modern plant in the world to manufacture molded glass pharmaceutical packaging. The construction lasted 13 months. The 13-hectare site benefits from a state-of-the art equipment (electrical and oxy-gaz furnaces) enabling an outage daily capacity of 1 million bottles and 20.000 tons per year.
The acquisition of an India-based manufacturer of Type I allows SGD Pharma to enter the tubular conversion market and to serve the fast-growing Indian pharmaceutical market.
Introduction of EasyLyo. EasyLyo provides a stronger packaging that is more resistant and suitable to extreme conditions encountered during the lyophilization process. EasyLyo is a range of Type I glass vials combining the strength of molded glass with superior cosmetic quality and weight reduction.
Oaktree Capital Management Ltd, an American investment firm, enters the Group’s capital on February 4th.
Acquisition of the Société de Services Verriers (SSV) company in France, dedicated to the sorting of pharmaceutical containers, which is a new activity for SGD Pharma.
Saint-Gobain Desjonquères becomes SGD Group. SGD Pharma is the first molded glass manufacturer to obtain the ISO 15378 certifications for all its pharmacy sites.
The acquisition of the Henri Desjonquères company by Saint-Gobain gives birth to Saint-Gobain Desjonquères, increasing its number of manufacturing sites worldwide: Kipfenberg (Germany), Santa Marina (Brazil), La Granja (Spain).
The furnace 4 at the Mers-les-Bains (France) factory is dedicated to the production of Type I molded glass.
Automation of the Mers-les-Bains (France) factory with IS machines.
Henri Desjonquères founds Verrerie du Tréport, a glass manufacture factory in Mers-les-Bains (France), primarily aimed at the luxury perfumery market. The molded glass bottles are hand-blown.